| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 3,071 | 3,157 | 3,250 | 3,417 | 4,144 | 4,424 | 4,243 | 4,511 | 4,209 | 3,839 | 3,952 | 3,929 | 4,125 | 3,960 | 4,122 | 3,872 | 3,922 | 3,922 | 4,007 | 3,844 | 4,084 | 3,513 | 3,807 | 3,939 | 3,808 | 4,265 | 4,076 | 4,122 | 3,880 | 3,610 | 4,106 | 4,263 | 4,368 | 4,765 | 4,980 | 5,109 | 4,924 | 5,582 | 5,539 | 5,672 | 5,619 | 6,243 | 6,921 | 7,215 | 7,533 | 8,348 |
| Expenses | 2,289 | 2,331 | 2,667 | 2,702 | 2,883 | 3,157 | 3,260 | 3,264 | 3,472 | 3,104 | 3,099 | 3,287 | 4,789 | 3,329 | 3,401 | 3,608 | 3,107 | 3,131 | 3,788 | 3,629 | 3,320 | 3,040 | 3,254 | 3,239 | 3,066 | 3,306 | 5,415 | 3,791 | 3,615 | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,160 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 5,332 | 5,120 | 5,827 |
| EBITDA | 783 | 825 | 583 | 715 | 1,261 | 1,268 | 983 | 1,246 | 737 | 735 | 853 | 642 | -665 | 631 | 721 | 264 | 814 | 791 | 219 | 215 | 763 | 473 | 553 | 700 | 742 | 960 | -1,339 | 331 | 265 | 98 | 414 | 473 | 515 | 807 | 859 | 950 | 960 | 1,223 | 1,207 | 1,261 | 1,273 | 1,702 | 2,215 | 1,883 | 2,412 | 2,520 |
| Operating Profit % | 25 % | 24 % | 16 % | 19 % | 30 % | 27 % | 23 % | 26 % | 17 % | 18 % | 20 % | 16 % | -20 % | 12 % | 13 % | 6 % | 18 % | 18 % | 1 % | 2 % | 12 % | 12 % | 14 % | 17 % | 18 % | 22 % | -35 % | 7 % | 6 % | 3 % | 10 % | 11 % | 11 % | 17 % | 17 % | 18 % | 19 % | 21 % | 21 % | 21 % | 22 % | 26 % | 31 % | 25 % | 31 % | 29 % |
| Depreciation | 107 | 101 | 116 | 122 | 149 | 203 | 211 | 231 | 267 | 261 | 272 | 280 | 273 | 259 | 266 | 219 | 219 | 250 | 253 | 253 | 214 | 215 | 213 | 244 | 216 | 209 | 919 | 203 | 327 | 193 | 204 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 272 | 393 | 299 | 317 | 313 | 447 | 453 |
| Interest | 3 | 7 | 24 | 10 | 31 | 35 | 29 | 48 | 41 | 44 | 48 | 54 | 59 | 69 | 74 | 79 | 84 | 84 | 83 | 89 | 107 | 44 | 34 | 31 | 32 | 34 | 34 | 33 | 42 | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 |
| Profit Before Tax | 697 | 792 | 581 | 781 | 1,170 | 1,156 | 822 | 1,045 | 520 | 494 | 611 | 383 | -941 | 384 | 441 | 93 | 591 | 518 | -54 | -73 | 496 | 273 | 360 | 525 | 518 | 751 | -2,205 | 167 | -85 | 2 | 210 | 246 | 259 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 |
| Tax | 136 | 224 | 158 | 255 | 417 | 273 | 159 | 410 | 137 | 137 | 154 | 161 | -163 | 181 | 173 | 245 | 294 | 216 | 70 | 767 | 105 | 164 | 147 | 84 | 54 | 202 | -110 | -382 | 427 | 89 | 75 | 89 | 16 | 106 | 134 | 117 | 130 | 188 | 195 | 212 | 114 | 194 | 522 | 342 | 459 | 600 |
| Net Profit | 561 | 568 | 422 | 526 | 753 | 883 | 663 | 636 | 384 | 357 | 457 | 222 | -778 | 203 | 269 | -152 | 296 | 303 | -123 | -840 | 391 | 109 | 214 | 441 | 464 | 548 | -2,095 | 549 | -512 | -87 | 135 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 860 | 859 | 782 | 1,222 | 1,485 | 1,181 | 1,469 | 1,417 |
| EPS in ₹ | 12.17 | 12.65 | 9.34 | 11.67 | 16.63 | 19.57 | 14.69 | 14.04 | 8.42 | 7.93 | 10.07 | 4.91 | -17.33 | 6.40 | 5.88 | -3.37 | 6.55 | 6.69 | -2.72 | -18.56 | 8.64 | 2.36 | 4.66 | 9.67 | 10.15 | 11.96 | -46.22 | 12.01 | -11.40 | -1.96 | 2.85 | 3.38 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.70 | 18.75 | 16.93 | 26.70 | 32.36 | 25.74 | 34.83 | 30.95 |
Lupin
Lupin
2,300.00
-63.50
(-2.69%)
Market Cap
1,05,163.48 Cr
PE Ratio
19.44
Volume
37,62,236.00
Day High - Low
2,362.80 - 2,235.00
52W High-Low
2,529.50 - 1,855.00
Q1 Quarterly Results are out. Check out the updated financials3 days ago
View
Key Fundamentals
Market Cap
1,05,163.48 Cr
EPS
116.75
PE Ratio
19.44
PB Ratio
4.81
Book Value
490.96
EBITDA
9,240.40
Dividend Yield
0.76 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
23.79
Debt to Equity
0.30
Analyst Rating and Forecast
- By Refinitiv from36 analysts
Actual
Company News
View All News
Lupin Receives US FDA Approval for Sodium Zirconium Cyclosilicate6 hrs ago
Lupin has received US FDA approval for Sodium Zirconium Cyclosilicate Oral Suspension, marking a significant regulatory milestone for the pharmaceutical company.
Lupin's U.S. Business Targets Growth From FY2815 hrs ago
Lupin anticipates its U.S. business to return to growth starting fiscal year 2028, backed by a strong pipeline of exclusive first-to-files, biosimilars, and 505(B)(2) products.
Lupin Targets High Single-Digit Growth, 25% EBITDA15 hrs ago
Lupin confirms expectations for high single-digit revenue growth and ~25% EBITDA margins, with U.S. business forecast between $1.1 billion and $1.2 billion.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,944.40 | #1 4,66,526.69 | 38.59 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 51.77 | |
8,300.00 | 2,20,338.92 | 74.86 | 11,067.00 | 13.95 | 2,568 | 65.50 | 73.18 | |
4,924.00 | 1,87,293.13 | 87.37 | 13,886.20 | 20.34 | 2,138 | 3.28 | 51.57 | |
1,467.70 | 1,18,567.46 | 35.44 | 29,044.60 | 2.24 | 3,870 | -39.18 | 57.39 | |
1,119.00 | 1,12,597.58 | 21.71 | 27,657.90 | 17.64 | 5,026 | 7.82 | 50.30 | |
2,300.00 | #6 1,05,163.48 | #1 19.44 | #5 29,038.90 | #1 26.75 | #2 5,356 | #6 16.00 | 35.94 | |
2,438.00 | 1,00,688.42 | 48.72 | 14,636.40 | 14.85 | 1,938 | 29.13 | 43.44 | |
1,854.00 | 1,00,089.41 | 91.92 | 6,867.80 | 22.01 | 890 | #1 123.93 | 79.60 | |
1,158.80 | 96,721.45 | 30.73 | 35,058.60 | 3.90 | 4,158 | -69.10 | 35.65 | |
1,648.00 | 94,822.28 | 26.00 | 34,145.20 | 5.56 | 3,503 | 25.21 | 63.22 |
Growth Rate
Revenue Growth
26.75 %
Net Income Growth
61.98 %
Cash Flow Change
144.49 %
ROE
24.42 %
ROCE
33.49 %
EBITDA Margin (Avg.)
33.03 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 | 38,365 |
| Fixed Assets | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 | 10,994 |
| Current Assets | 7,832 | 9,887 | 11,953 | 12,210 | 13,854 | 15,413 | 13,986 | 12,458 | 12,451 | 13,448 | 16,799 | 24,027 |
| Capital Work in Progress | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 | 1,016 |
| Investments | 1,656 | 16 | 2,136 | 262 | 2,296 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 | 3,670 |
| Other Assets | 6,538 | 11,189 | 11,305 | 13,084 | 12,928 | 13,732 | 12,209 | 12,393 | 12,846 | 13,272 | 17,823 | 22,685 |
| Total Equity & Liabilities | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 | 38,365 |
| Current Liabilities | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,498 | 9,265 | 8,502 | 8,961 | 12,651 |
| Non Current Liabilities | 510 | 6,368 | 6,955 | 7,593 | 8,030 | 3,178 | 1,316 | 1,101 | 1,148 | 1,122 | 2,949 | 3,200 |
| Total Equity | 8,898 | 11,196 | 13,532 | 13,617 | 13,789 | 12,581 | 13,858 | 12,222 | 12,543 | 14,374 | 17,294 | 22,513 |
| Reserve & Surplus | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 | 22,357 |
| Share Capital | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 | 560 | 2,624 |
| Investing Activities | -1,034 | -6,769 | -2,527 | 470 | -3,283 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 | -4,172 | -3,865 |
| Operating Activities | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | 3,000 | 7,335 |
| Financing Activities | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 | 1,732 | -846 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 46.86 % | 46.84 % | 46.83 % | 46.81 % | 46.78 % | 47.10 % | 47.11 % | 47.10 % | 47.08 % | 47.07 % | 47.05 % | 47.04 % | 47.01 % | 46.98 % | 46.96 % | 46.95 % | 46.92 % | 46.90 % | 46.90 % | 46.89 % | 46.86 % | 46.85 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.11 % | 18.28 % | 19.32 % | 21.50 % | 22.04 % | 21.46 % | 21.25 % | 20.49 % | 21.49 % | 21.71 % | 22.42 % |
| DIIs | 22.08 % | 21.68 % | 24.38 % | 24.76 % | 26.84 % | 26.82 % | 27.54 % | 29.38 % | 29.21 % | 28.98 % | 29.42 % | 29.73 % | 27.76 % | 26.78 % | 25.09 % | 24.74 % | 25.41 % | 25.56 % | 26.55 % | 25.58 % | 25.32 % | 24.65 % |
| Government | 0.29 % | 0.28 % | 0.28 % | 0.28 % | 0.29 % | 0.29 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % |
| Public / Retail | 10.02 % | 9.91 % | 10.18 % | 9.99 % | 8.53 % | 8.59 % | 8.41 % | 8.06 % | 7.86 % | 7.06 % | 6.24 % | 5.87 % | 5.70 % | 5.65 % | 5.29 % | 5.17 % | 5.10 % | 5.23 % | 5.12 % | 5.10 % | 5.05 % | 5.06 % |
| Others | 20.75 % | 21.29 % | 18.34 % | 18.16 % | 17.57 % | 17.19 % | 16.94 % | 15.45 % | 15.85 % | 16.89 % | 17.27 % | 1.23 % | 1.23 % | 1.26 % | 1.15 % | 1.10 % | 1.10 % | 1.05 % | 0.94 % | 0.93 % | 1.06 % | 1.02 % |
| No of Share Holders | 0 | 2,93,782 | 3,02,292 | 3,61,288 | 3,61,862 | 3,78,547 | 3,82,828 | 3,78,011 | 3,60,677 | 3,22,678 | 2,89,074 | 2,81,542 | 2,80,248 | 2,88,537 | 2,79,280 | 2,81,988 | 2,83,210 | 2,86,604 | 2,80,256 | 2,88,931 | 2,90,411 | 3,00,283 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 7.5 | 5 | 5 | 6 | 6.5 | 4 | 4 | 8 | 12 | 18 |
| Dividend Yield (%) | 1.02 | 0.68 | 0.85 | 0.59 | 0.87 | 0.61 | 0.25 | 0.39 | 0.52 | 0.76 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Jul 2021 |  Dividend | ₹ 6.50 /share | 27 Jul 2021 | 1,212.25 | 1,111.60 |
| 15 Jul 2022 | Dividend | ₹ 4.00 /share | 14 Jul 2022 | 683.30 | 643.20 |
| 14 Jul 2023 | Dividend | ₹ 4.00 /share | 14 Jul 2023 | 732.25 | 930.75 |
| 16 Jul 2024 | Dividend | ₹ 8.00 /share | 16 Jul 2024 | 1,655.25 | 1,832.10 |
| 02 Aug 2024 |  Annual General Meeting | NA | 02 Aug 2024 | 1,778.90 | 1,953.55 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 2,151.95 | 2,166.05 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 2,134.25 | 2,169.40 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 2,107.70 | 2,063.00 |
| 25 Jul 2025 | Dividend | ₹ 12.00 /share | 25 Jul 2025 | 2,063.00 | 1,943.40 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 1,930.85 | 1,882.20 |
| 11 Aug 2025 | Annual General Meeting | NA | 11 Aug 2025 | 1,894.70 | 1,918.00 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 1,943.35 | 1,997.00 |
| 12 Feb 2026 | Quarterly Result Announcement | NA | 12 Feb 2026 | 2,150.50 | 2,209.10 |
| 07 May 2026 | Quarterly Result Announcement | NA | 07 May 2026 | 2,311.50 | 2,442.90 |
| 17 Jul 2026 | Dividend | ₹ 18.00 /share | 17 Jul 2026 | 2,442.90 | 2,500.05 |
| 04 Aug 2026 | Annual General Meeting | NA | 04 Aug 2026 | 2,490.20 | 2,376.00 |
| 06 Aug 2026 | Quarterly Result Announcement | NA | 06 Aug 2026 | 2,514.80 | 2,386.00 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
6 hrs ago
6 hrs agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 hrs ago
8 hrs agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
4 days agoBoard Meeting Outcome For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026.4 days ago
4 days agoBoard Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026.4 days ago
4 days agoShareholder Meeting / Postal Ballot-Scrutinizers Report6 days ago
6 days agoShareholder Meeting / Postal Ballot-Outcome of AGM6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 22, 2026
Jul 22, 2026Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026.Jul 22, 2026
Jul 22, 2026Announcement under Regulation 30 (LODR)-AcquisitionJul 21, 2026
Jul 21, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 14, 2026
Jul 14, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 14, 2026
Jul 14, 2026Business Responsibility and Sustainability Reporting (BRSR)Jul 13, 2026
Jul 13, 2026Reg. 34 (1) Annual Report.Jul 13, 2026
Jul 13, 2026Notice Of The Forty-Fourth Annual General Meeting Of The Company And Integrated Report For FY 2025-26.Jul 13, 2026
Jul 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 09, 2026
Jul 09, 2026Intimation Of Record Date For Payment Of Final Dividend.Jul 08, 2026
Jul 08, 2026Intimation Of The Forty-Fourth Annual General Meeting.Jul 08, 2026
Jul 08, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 08, 2026
Jul 08, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2026
Jul 08, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 06, 2026
Jul 06, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 01, 2026
Jul 01, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 01, 2026
Jul 01, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 01, 2026
Jul 01, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 30, 2026
Jun 30, 2026Closure of Trading WindowJun 26, 2026
Jun 26, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 26, 2026
Jun 26, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 22, 2026
Jun 22, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 17, 2026
Jun 17, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 08, 2026
Jun 08, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 04, 2026
Jun 04, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 03, 2026
Jun 03, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 03, 2026
Jun 03, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 29, 2026
May 29, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 29, 2026
May 29, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2026
May 28, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2026
May 28, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 22, 2026
May 22, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 18, 2026
May 18, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2026
May 15, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 14, 2026
May 14, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 43.00
ATR(14)
Volatile 53.53
STOCH(9,6)
Neutral 33.26
STOCH RSI(14)
Oversold 7.94
MACD(12,26)
Bearish -11.09
ADX(14)
Weak Trend 16.90
UO(9)
Bearish 38.49
ROC(12)
Downtrend And Accelerating -1.80
WillR(14)
Oversold -87.21
About Lupin
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The...more
Website
Chairperson NameM D Gupta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
